Benitec Biopharma Inc. (BNTC) research
Benitec Biopharma Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $8.98
- As of
Benitec Biopharma Inc. (BNTC): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-30.
As of . Source: SEC EDGAR filings for BNTC. Method and limitations.
Share the BNTC intelligence card
See the full BNTC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BNTC on one page. Preview it with sample data, then open it live with a free account.
Preview the BNTC dossierActive signals for BNTC
- mediumEARNINGS_BEAT
Q4-2026: Beat consensus by 5.6%, EPS $-0.26 vs $-0.2754 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +363% to BNTC (2026Q2)
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 42.0% - EPS $-0.42 vs $-0.2958 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 41.4% - EPS $-0.22 vs $-0.3757 estimate
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 14.1% - EPS $-0.26 vs $-0.2278 estimate
FREE, NO ACCOUNT
Every signal on BNTC, as it fires
You are seeing 5 of 6 signals recorded on BNTC since 2026-05-26.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BNTC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 08205P209 · 2026Q2 | $12.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 08205P209 · 2026Q2 | $1.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BNTC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BNTC mentioned in Kresmion daily briefs
BNTC against its peers
BNTC's return on equity of -25.7% ranks in the 82nd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | BNTC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 14.2M | n/a | 17 |
| Operating margin | n/a | -271.9% | n/a | 15 |
| Net margin | n/a | -157.4% | n/a | 15 |
| Return on equity | -25.7% | -54.2% | 82 | 18 |
Peers (22): ARTV, OCGN, EBS, BBOT, SRZN, CABA, PROK, LRMR, OBIO, FENC, EVMN, PRLD, ARCT, IRD, LXEO, AGEN, VNDA, IPSC, CCCC, RZLT, ABEO, RCKT. Left out: VOGX (no annual filing), ENTA (period gap), CUVL (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (BNTC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more BNTC signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BNTCand get the insider, 13F, options, and confluence read in one view.